Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 4/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 5/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879657 | 0.83 | PDCD1 (0.33) | PIM1PDCD1CD274ITGA2BGPR119 | |
| SCHEMBL3883722 | 0.81 | CNR2 (0.43) | CNR2PARP1PIM1PIM3PIM2 | |
| SCHEMBL3883724 | 0.81 | CNR2 (0.42) | CNR2PARP1PIM1PIM3PIM2 | |
| SCHEMBL3879513 | 0.79 | CNR2 (0.43) | CNR2PARP1PIM1PIM3PIM2 | |
| SCHEMBL3879640 | 0.74 | PDCD1 (0.38) | PDCD1CD274 | |
| SCHEMBL3880206 | 0.72 | TDO2 (0.39) | CCNCCDK8PDCD1CD274 | |
| SCHEMBL3880210 | 0.69 | TDO2 (0.39) | CCNCCDK8 | |
| SCHEMBL20783864 | 0.69 | CNR2 (0.46) | CNR2 | |
| SCHEMBL3878538 | 0.69 | NPC1 (0.37) | PARP1PDCD1CD274 | |
| SCHEMBL24894780 | 0.68 | CNR2 (0.48) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
| EP-1858900-A1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006097691-A1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH2 | CNR2 79/4885PARP1 4142/4885PIM1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.